Hydration Pharmaceuticals Company Limited
AASX:HPC0.00
AUD
0.00
(0.00%)
ISIN
AU0000187957
Return %
Stock
S&P 500
1Y
-62.50
14.20
3Y
-91.89
81.12
5Y
- -
68.34
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Semi-annual Revenue
USD
•
in mil. unless spec.Semi-annual Earnings Per Share
USD
•
in mil. unless spec.Semi-annual Dividends Per Share
USD
•
in mil. unless spec.Company Description
- CEO
- Oliver Baker
- Full Time Employees
- 3
- Sector
- Retail trade
- Industry
- Food retail
- Address
- 6 Palmer Parade, Cremorne Cremorne VIC Australia 3121
- IPO Date
- Dec 10, 2021
- Website
- hydralyte.com
- Similar Companies
- Business
- The Hydration Pharmaceuticals Company Limited (ASX:HPC) markets and distributes healthy hydration products under the Hydralyte brand, including liquid solutions, effervescent tablets, and powder formulations designed for electrolyte replenishment and consumer healthcare needs such as hydration support, immune system support, energy support, liver support, metabolic support, gut barrier support, hair growth, stronger nails, and decreased wrinkle depth; these products feature premium, gluten-free, non-GMO ingredients and are sold through wholesale suppliers, online retailers, and retail stores. The company, founded in 2001 and headquartered in Melbourne, Australia, primarily focuses on the North American market, particularly the United States and Canada, following the divestment of its non-US business and assets to Prestige Consumer Healthcare Inc. for A$13.7 million in October 2024, which enabled full debt repayment and provision of capital for US growth initiatives; it holds distribution rights to Hydralyte globally outside Australia, New Zealand, Asia (excluding China, including Hong Kong but excluding Taiwan), Africa, and the Middle East (excluding Turkey). Recent developments include execution of a variation to its facility agreement with PURE Asset Management for A$1.7 million in new funding to support a potential sale transaction, leadership changes with Oliver Baker appointed as CEO and Managing Director in May 2024 alongside Nicholas Berry and continued service by Chairman Adem Karafili, and director share purchases such as Joseph Constable's acquisition of shares in June 2025; the firm operates in the consumer staples sector's personal products segment, targeting health-conscious consumers seeking oral rehydration solutions.